Notably, TGF-B inhibition has recently emerged as a novel approach for the treatment of MDS, highlighting the therapeutic impact of targeting the bone marrow microenvironment in MDS [63]. This evidence concerns the gene TGFB1 and myelodysplastic syndrome.